Nexalin Technology Appoints Medical Device Veteran Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory

Nexalin Technology, Inc.

HOUSTON, Jan. 24, 2023 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW)today announced the appointment of Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory.

Mr. Nketiah is a regulatory, clinical and quality assurance expert specializing in US FDA and international regulatory approvals, with more than 23 years of experience working directly with the FDA in the medical device and life sciences industries, both for and OTC products. His experience includes multiple regulatory filings of 510(k)s, PMAs, De Novo, IDEs, Q-Submissions, FDA meetings and international regulatory approvals for a wide variety of innovative and new medical device and in vitro diagnostics companies . His experience includes developing quality systems, writing several US FDA regulatory submissions and assisting with clinical operations. Mr. Nketiah also has extensive experience in obtaining US and international approvals for clinical trials and/or product launches in Europe, North America, Australia/New Zealand and Asia. Prior to joining Nexalin, Mr. Nketiah held senior positions at several companies, including VP of Quality & Regulatory Affairs at Intervenn Bioscience, Tivic Health, Previvo Genetics, Sr. Director of Quality and Regulatory Affairs at PROCEPT BioRobotics, Director of Quality at Crux Biomedical, Inc. and at Biomimedica, Inc. Michael holds two Bachelor of Science degrees in chemistry and mechanical engineering and an MBA degree.

Mark White, CEO of Nexalin Technology, commented, “We are pleased to welcome Michael to our senior leadership team. He brings extensive program management, clinical development and regulatory experience, which should prove invaluable as we accelerate our efforts to gain FDA clearance/clearance of our Generation 2 (Gen-2) and Generation 3 (Gen-3) ) neurostimulation devices, which we believe will significantly improve healthcare outcomes in patients with mental and neurodegenerative diseases as an alternative to psychiatric drugs. Our Gen-2 device, with a new and improved modern housing, as well as an advanced waveform emitted at 15 milliamps, is designed to penetrate deeper into the brain to stimulate structures related to mental illness for better response of the patient. We are also advancing clinical development of our Gen-3 prototype, a new patient headset for the treatment of anxiety and insomnia that uses a virtual clinic model and can be performed from the privacy of the patient’s home while reducing costs for patients. lowered and doctors. Having a widely respected clinical expert of Michael’s caliber will help us advance clinical trials of our Gen-2 and Gen-3 devices in the United States as we seek to expand our innovative neurostimulation devices to new indications, such as substance use disorders (addiction). ), Alzheimer’s, traumatic brain injury (TBI), PTSD and chronic pain. Michael has a proven track record of launching new commercial products, and we look forward to using his skills to bring our new, effective, safe and drug-free therapy to patients with mental health problems in the United States, China and the rest of the world. world.”

About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. All Nexalin products are non-invasive and undetectable to the human body, providing relief to people with mental health issues without any adverse side effects. Nexalin uses bioelectronic medical technology to treat mental health problems without the need for drugs or psychotherapy. Nexalin believes the 15-milliamp medical device can penetrate deep into the midbrain structures associated with mental disorders. Nexalin believes that the deeper penetrating waveform will generate an enhanced patient response with no adverse side effects. The Nexalin tACS device was recently approved in China by the National Medical Products Administration (NMPA) for the treatment of insomnia and depression. In September 2018, Nexalin entered into a series of agreements with Wider Come Limited (“Wider”), a company incorporated under the laws of the People’s Republic of China. Pursuant to this agreement, Nexalin and Wider have agreed to explore the creation of a joint venture entity to be located in Hong Kong. This new entity will conduct clinical research and implement a corporate distribution plan for the Nexalin device in the Asia Pacific region. Additional information about the company is available at: https://nexalin.com/.

FORWARD-LOOKING STATEMENTS

This press release contains statements that constitute “forward-looking statements”, including with respect to the company’s initial public offering. Forward-looking statements are subject to numerous conditions, many of which are beyond the Company’s control, including those set forth in the Risk Factors section of the Company’s registration statement and prospectus for the offering filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. The Company assumes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact:
Crescendo Communications, LLC
Phone: (212) 671-1020

Email: [email protected]

Nexalin Technology Appoints Medical Device Veteran Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory

Leave a Reply

Your email address will not be published.

Scroll to top